Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, Zhang Q, Freelander A, Leventhal MJ, Feit A, Cohen Feit G, Feiglin A, Liu W, Hermida-Prado F, Kesten N, Ma W, De Angelis C, Morlando A, O'Donnell M, Naumenko S, Huang S, Nguyen QD, Huang Y, Malorni L, Bergholz JS, Zhao JJ, Fraenkel E, Lim E, Schiff R, Shapiro GI, Jeselsohn R. Guarducci C, et al. Among authors: lim e. Clin Cancer Res. 2024 May 1;30(9):1889-1905. doi: 10.1158/1078-0432.CCR-23-2975. Clin Cancer Res. 2024. PMID: 38381406 Free PMC article.
CDK7-dependent transcriptional addiction in triple-negative breast cancer.
Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. Wang Y, et al. Among authors: lim e. Cell. 2015 Sep 24;163(1):174-86. doi: 10.1016/j.cell.2015.08.063. Cell. 2015. PMID: 26406377 Free PMC article.
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI. Johnson SF, et al. Among authors: lim e. Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077. Cell Rep. 2016. PMID: 27880910 Free PMC article.
Sensitizing HR-proficient cancers to PARP inhibitors.
Lim E, Johnson SF, Geyer M, Serra V, Shapiro GI. Lim E, et al. Mol Cell Oncol. 2017 Mar 3;4(6):e1299272. doi: 10.1080/23723556.2017.1299272. eCollection 2017. Mol Cell Oncol. 2017. PMID: 29209638 Free PMC article. No abstract available.
Estrogen receptor signaling is reprogrammed during breast tumorigenesis.
Chi D, Singhal H, Li L, Xiao T, Liu W, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao P, Long H, Garber J, Brown M. Chi D, et al. Among authors: lim e. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11437-11443. doi: 10.1073/pnas.1819155116. Epub 2019 May 20. Proc Natl Acad Sci U S A. 2019. PMID: 31110002 Free PMC article.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E. Portman N, et al. Among authors: lim e. Breast Cancer Res. 2020 Aug 12;22(1):87. doi: 10.1186/s13058-020-01318-2. Breast Cancer Res. 2020. PMID: 32787886 Free PMC article.
2,744 results